pentobarbital raises toxicity of buprenorphine, prolonged-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Intently. Coadministration of buprenorphine and benzodiazepines or other CNS depressants boosts chance of adverse reactions which include overdose, respiratory depression, and Dying. Cessation of benzodiazepines or other CNS depressants is most popular normally.

Right after stopping a CYP3A4 inducer, because the effects on the inducer decrease, the fentanyl plasma concentration will increase which could increase or prolong both of those the therapeutic and adverse effects.

pentobarbital increases toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check. CYP3A4 inducers may perhaps boost the metabolism of ifosfamide to its active alkylating metabolites.

pentobarbital will lower the extent or effect of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

pentobarbital decreases levels of vandetanib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay away from coadministration with strong CYP3A4 inducers; these drugs minimize exposure to vandetanib by as many as 40%.

Contraindicated. Coadministration of doravirine with a robust CYP3A inducer could reduce doravirine plasma concentrations and/or effects. Possible for lack of virologic reaction and possible resistance to doravirine.

With therapeutic doses of TCAs, barbiturates raise metabolism and decrease blood concentrations of TCAs.

The efficacy of hormonal contraceptives can be lowered. Use an alternate technique of contraception or possibly a backup method when enzyme inducers are utilised with merged hormonal contraceptives (CHCs), and continue backup contraception for 28 times following discontinuing enzyme inducer to guarantee contraceptive trustworthiness.

pentobarbital will minimize the extent or result of sunitinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

pentobarbital will reduce the level or influence of mavacamten by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

pentobarbital will minimize the level or impact of vincristine by affecting more info hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Mysterious.

pentobarbital will reduce the level or result of loratadine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

pentobarbital will minimize the extent or impact of nilotinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

pentobarbital will reduce the extent or influence of pimavanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. Stay clear of coadministration if possible. Check for lowered pimavanserin efficacy. A rise in pimavanserin dosage may very well be desired.